Table 3.
Associations between plasma biomarkers and neuroimaging indicators
| Fazekas score (n = 57) | Lacunes (n = 57) | CMBs (n = 47) | ||
|---|---|---|---|---|
| NfL | ρ (95% CI)* | 0.02 (− 0.26, 0.29) | 0.09 (− 0.19, 0.36) | 0.32 (0.03, 0.56) |
| β (95% CI)† | 0.03 (− 0.14, 0.19) | 0.09 (− 0.17, 0.35) | 0.16 (0.02, 0.30) | |
| GFAP | ρ (95% CI)* | 0.23 (− 0.05, 0.47) | − 0.07 (− 0.34, 0.21) | 0.37 (0.08, 0.60) |
| β (95% CI)† | 0.05 (− 0.13, 0.23) | − 0.03 (− 0.31, 0.25) | 0.15 (− 0.02, 0.33) | |
| Tau | ρ (95% CI)* | − 0.08 (− 0.35, 0.20) | 0.08 (− 0.20, 0.34) | 0.08 (− 0.23, 0.36) |
| β (95% CI)† | − 0.01 (− 0.19, 0.18) | 0.07 (− 0.21, 0.35) | 0.08 (− 0.08, 0.24) | |
| UCHL1 | ρ (95% CI)* | 0.01 (− 0.27, 0.29) | − 0.13 (− 0.39, 0.16) | 0.08 (− 0.23, 0.36) |
| β (95% CI)† | 0.02 (− 0.15, 0.20) | − 0.13 (− 0.41, 0.14) | 0.06 (− 0.10, 0.21) |
Numbers in bold indicate statistical significance
CMBs cerebral microbleeds, GFAP glial fibrillary acidic protein, NfL neurofilament light chain, UCHL1 ubiquitin carboxy-terminal hydrolase L1
*Spearman’s rank correlation partially adjusted for age and sex. †Multiple linear regression analysis adjusted for age, sex, and hypertension